US2809916A - Sustained release pharmaceutical preparations - Google Patents
Sustained release pharmaceutical preparations Download PDFInfo
- Publication number
- US2809916A US2809916A US541027A US54102755A US2809916A US 2809916 A US2809916 A US 2809916A US 541027 A US541027 A US 541027A US 54102755 A US54102755 A US 54102755A US 2809916 A US2809916 A US 2809916A
- Authority
- US
- United States
- Prior art keywords
- produce
- drying
- mixing
- crushing
- granular material
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
Definitions
- enteric coating is one which will resist the action of the gastric juices in the stomach and will not dissolve therein or be otherwise affected thereby so that the drug which is incorporated in the tablet will pass through the stomach and into the intestine.
- enteric coating is of such a nature that it will be dissolved very readily in the intestinal fluid-s so that the drug which has been enclosed in the enteric coating will become effective in the intestinal tract rather than in the stomach.
- Such tablets are merely delayed action tablets.
- enteric coated tablet is also used when it is desirable to introduce the medicament into the pati'ents intestinal tract without discharging any of the medicament into the stomach.
- enteric coatings are not particularly accurate and the enteric coatings now in use are not always completely reliable.
- enteric coatings are dissolved to an appreciable extent in the gastric juices of the stomach or at least are attacked by such gastric juices to such an extent as to lose physical or structural strength, a factor which has been hitherto overlooked.
- peristalic action is severe enough to disrupt the physically weakened enteric coating and the drum or medicament enters the system with a surge, as has been discovered by blood level studies.
- enteric coatings however efficient or inefiicient they may be, merely withhold the medicament for some timedelay period and then release it to the patients system in the same surge dose as though the period of time delay had not occurred. In other words, the patient ultimately gets the surge.
- *It is the primary object of the present invention, therefore, to provide a pharmaceutical preparation having a unique and novel composition and structure, which, as a result of a drug or medicament, can be administered in a persistent sustained incremental dosage.
- V i is the primary object of the present invention, therefore, to provide a pharmaceutical preparation having a unique and novel composition and structure, which, as a result of a drug or medicament, can be administered in a persistent sustained incremental dosage.
- a pharmaceutical preparation adapted for sustained minute-incremental dosage can be made by intimately mixing various enteric water insoluble excipients, such as shellac, with powdered drugs to form a somewhat pasty mass which is then spread on drying trays and dried to produce a rough granular material.
- This granular material is crushed and remixed with the excipient to form a pasty mass which is then spread on trays and dried again to form .a rough granular material.
- This procedure of crushing, mixing with excipient, and tray-drying is repeated a number of times and finally the end product is screened to produce agranular material having granules of substantially uniform size.
- Example I enough shellac (of the,type above) until a pasty mass results. This mass is again placed on cloth drying trays .and dried, thereby again forming a granular mass as before.
- the above procedure is repeated for a total of eleventimes, using a total of about 12 gallon of shellac (dry solids content 46%).
- The-first four mixing-drying steps are repeated over a time cycle which involves about 7 to 10 hour drying periods and all subsequent mixing-drying steps include about 20 to 22 hour drying periods. These time periods can be speeded up by placing the drying trays in a hot room. The hot room should be maintained at about 100 to 120 F.
- the granules are-precisely uniform in constituency. :In other words, any given weight of granules will be found 'to contain theisarne dosage of amphetamine. Of course, each-batch should be assayed and the actual amphetamine content by weight or percentage determined. It has been found that by following a standardized manufacturing procedure, successive batches of granules have closely similar assays well Within admissible limits of pharmaceutical accuracy. However,
- Example 1 Adry mixture of .3 oz. d-arnphetamine sulfate, .12 oz. secobarbital and 3 lbs. dicalcium phosphate is taken up with Shellac as per'Example I employing approximately 1 gallon shellac in eleven successive mixing-dryingsteps.
- Example III A dry mixture of 7 oz. pentobarbituric acid, 7 oz. phenobarbital and 2 oz. -d-amphetamine sulfate, 3 lbs. calcium carbonate is taken up in shellac as per Example I employing nine successive mixing-drying steps.
- Example IV A. dry mixture of 2 oz. scopolamine aminoxidehydrobromide, and 5 lbs. dicalcium phosphate were taken up in shellac as per Example Iemploying-eleven successive mixing-dryingsteps.
- Example V A dry mixture of 2 lbs. mephobarbital, 2 /2 oz. homatropine methylbromide, 1 oz. atropine methyl nitrate, /2 oz. hyoscine hydrobromide, and 6 lbs. kaolin were taken up in shellac as per Example I employing eleven successive mixing-drying steps.
- Example VI A dry mixture of 4 lbs. mannitol hexanitrate 7% (with 13 parts lactose) was taken up in shellac as per Example I employing eleven successive mixing-drying steps.
- Example VII A dry mixture of 3 lbs. pyralimine maleate and 1 lb. vitamin C were taken up in 60 oz. (liquid) of shellac as per Example I employing fifteen successive mixing-drying steps to produce 5.5 lbs. of finished granules. 275 mgs. of such granules were filled into a No. 3 capsule, giving a dosage of mgs. ,pyralimine maleate and 50 mgs. of vitamin C.
- inert carriers such as calcium carbonate, tri-calcium phosphate, magnesium oxide, magnesium carbonate, kaolin, starch, or lactose, may be used. Where the drug or medicament has sufficient bulk, it-is even possible to eliminate the use of an inert carrier, as shown by Example VII.
- liquid excipients such as a mixture of castor oil, stearic acid, and confectioners glaze (i. e. shellac), cellulose acetate phthalate in acetone, salol in alcohol, various balsams, such as tolu in alcohol, ethyl cellulose in methyl-ethylketone, or zein in isopropanol, can be employed in practicingthe herein described invention. Similarly, by'increasing-the number of.
- mixing-drying steps it is possible to-slow down the rate of entry of the drug into the patients system and, conversely, by-lowering the number of-successive mixing-drying steps, it is possible to speed up the rate of entry of the drug into the patients system.
- a minimum of such steps is two and a practical maximum is'fifteen, sinceadditional mixing-drying steps resulting in such a slow rate of drug absorption by the patient has beenfound to be impractical forpresently known medical purposes.
- the granules can be placed in 'a coating pan and sugar coated with aplain or suitablycolored sugar glaze.
- sustained period minuteincremental dosage pharmaceutical preparations which comprise intimately mixing a powdered drug and an enteric water insoluble excipient to produce a pasty mass, drying the mass slowly without agitation in such a manner as to produce a rough granular material, breaking up the rough granular material by light crushing, whereby to reduce it to granular particles, said mixing, drying and crushing operations constituting one cycle, and remixing the granular particles with an additional quantity of the excipient to produce a pasty mass, redrying such pasty mass slowly and without agitation in such a manner as to produce a granular material, again breaking up the rough granular material by light crushing, whereby to reduce it again to granular particles, said second mixing, drying and crushing operations constituting a second cycle, said process consisting of not less than 3 nor more than 15 mixing, crushing and drying cycles repeated in successive order, whereby to produce a pharmaceutical material consisting of granules having slow but continuous and attenuated solubility in the gastro-intestinal tract
- the process for making sustained period minuteincremental dosage pharmaceutical preparations which comprises intimately mixing a powdered drug and a water insoluble excipient consisting of a mixture of shellac and stearic acid, whereby to produce a pasty mass, drying the mass slowly without agitation in such a manner as to produce a rough granular material, breaking up the rough granular material by light crushing, whereby to reduce it to granular particles, said mixing, drying and crushing operations constituting one cycle, and remixing the granular particles with an additional quantity of the excipient to produce a pasty mass, redrying such pasty mass slowly and without agitation in such a manner as to produce a granular material, again breaking up the rough granular material by light crushing, whereby to reduce it again to granular particles, said second mixing,
- drying and crushing operations constituting a second cycle, said process consisting of not less than three nor more than fifteen mixing, crushing and drying cycles repeated in successive order, whereby to produce a pharmaceutical material consisting of granules having slow but 7 continuous and attenuated Solubility in the gastro-intestinal tract.
- the process for making sustained period minuteincremental dosage pharmaceutical preparations which comprises intimately mixing a powdered drug and an enteric water insoluble excipient to produce a pasty mass, spreading the mass in a thin layer upon trays and drying the mass slowly without agitation in such a manner as to produce a rough granular material, breaking up the rough granular material by light crushing, whereby toreduce to granular particles, said mixing, drying and crushing operations constituting one cycle, and remixing the granular particles with an additional quantity of the excipient to produce a pasty mass, redrying such pasty mass slowly and without agitation in such a manner as to produce a granular material, again breaking up the rough granular material by light crushing, whereby to reduce it again to granular particles, said second mixing, drying and crushing operations constituting a second cycle, said process consisting of not less than three nor more than fifteen mixing, crushing and drying cycles repeated insuccessive order, whereby to produce a pharmaceutical material consisting of granules having slow
- the process for making sustained period minuteincremental dosage pharmaceutical preparations which comprises intimately mixing a powdered drug and an enteric water insoluble excipient to produce a pasty mass, spreading the mass in a thin layer upon air pervious trays and drying the mass slowly without agitation in such a manner as to produce a rough granular material, breaking up the rough granular material by light crushing, whereby to reduce it to granular particles, said mixing, drying and crushing operations constituting one cycle, and remixing the granular particles with an additional quantity of the excipient to produce a pasty mass, redrying such pasty mass slowly and without agitation in such a manner as to produce a granular material, again breaking up the rough granular material by light crushing, whereby to reduce it again to granular particles, said second mixing, drying and crushing operations constituting a second cycle, said process consisting of not less than three nor more than fifteen mixing, crushing and drying cycles repeated in successive order, whereby to produce a pharmaceutical material consisting of granules having slow but continuous
- the process for making sustained period minutemcremental dosage pharmaceutical preparations which comprises intimately mixing a powdered drug and an enteric water insoluble excipient to produce a pasty mass, spreading the mass in a thin layer upon cloth bottomed trays and drying the mass slowly without agitation in such a manner as to produce :a rough granular material, breaking up the rough granular material by light crushing, whereby to reduce it to granular particles, said mixing, drying and crushing operations constitutingone cycle, and remixing the granular particles with an additional quantity of the excipient to produce a pasty mass, redrying such pasty mass slowly and without agitation in such a manner as to produce a granular material, again breaking up the rough granular material by light crushing, whereby to reduce it again to granular particles, said second mixing, drying and crushing operations constituting a second cycle, said process consisting of not less than three nor more than fifteen mixing, crushing and drying cycles repeated in successive order, whereby to produce a pharmaceutical vmaterial consisting of granules
- Theprocess for making sustained period minuteincremental dosage pharmaceutical preparations which comprises intimately mixing a powdered drug and an enteric water insoluble excipient to produce apasty mass,
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
Description
SUSTAINED RELEASE PHARMACEUTICA PREPARATIONS Victor M. Hermelin, University City,
No Drawing. Application October 17, 1955, erial No. 541,027
12 Claims. (Cl. 167-32) This invention relates in general to certain new and useful improvements in pharmaceutical preparations and, more particularly, to medicated granules which release the medication into the human system gradually over a sustained period of time and methods of making the same. This application is a continuation-in-part of my copending application Serial No. 461,354, filed October 11, 1954, now Pat. No. 2,736,682, which is, in turn,
United States Patent U a continuation of an earlier application Serial No.
195,369, filed November 13, 1950, now abandoned.
It has been accepted practice in the compounding of pharmaceutical tablets to provide certain types of tablets with what has been commonly referred to as an enteric coating. The enteric coating is one which will resist the action of the gastric juices in the stomach and will not dissolve therein or be otherwise affected thereby so that the drug which is incorporated in the tablet will pass through the stomach and into the intestine. The so-called enteric coating is of such a nature that it will be dissolved very readily in the intestinal fluid-s so that the drug which has been enclosed in the enteric coating will become effective in the intestinal tract rather than in the stomach. Such tablets, however, are merely delayed action tablets. In other words, by selecting an enteric coating of the proper type and by using an appropriate amount, it is possible to delay the efiective entry of the drug into the patients system for a number of hours. The so-called enteric coated tablet is also used when it is desirable to introduce the medicament into the pati'ents intestinal tract without discharging any of the medicament into the stomach. These procedures are useful in certain applications, but the patient sooner or later receives the entire dosage in a single shot, so tospeak.
, Recently, efforts have been made to provide delayed dosage by surrounding an enteric coated core with a second layer or group of layers of medicament and then, largely for appearance, covering the resulting tablet, ellipsoid or sphere with a soluble sugar coating. The theory is that the sugar coating and outer layers dissolve 'in the stomach and almost immediately release the initial dosage which lasts the patient for several hours. Meanwhile, the enteric coated core will have reached the intestinal tract and will dissolve therein very rap-' idly, releasing the second dosage. Even if this theory were borne out in practice, the net result would merely be a spaced interval two shot" medication which is very little different in therapeutic effect from the simple business of giving the patient two smaller tablets at the same intervals. As a matter of fact, however, the existing methods of forming enteric coatings are not particularly accurate and the enteric coatings now in use are not always completely reliable. The research of Maney and Kuever (J. Am. Pharm. Soc. 30, 1941, p. 276), and of Abbott and Seeport (Pharm. J. 151, 1943, p. 52), suggests that various known enteric materials yield varying *results and some such coatings seem to resist disintegration for periods up to five or sixhours. Actual tests 2,809,916 Patented Oct. 15, 1957 with various types of enteric coatings using the in vitro method of Maney and Kuever have shown that most available enteric coatings dissolved to an appreciable extent in the gastric juices of the stomach or at least are attacked by such gastric juices to such an extent as to lose physical or structural strength, a factor which has been hitherto overlooked. In the stomach, peristalic action is severe enough to disrupt the physically weakened enteric coating and the drum or medicament enters the system with a surge, as has been discovered by blood level studies. The important point, however, is that enteric coatings, however efficient or inefiicient they may be, merely withhold the medicament for some timedelay period and then release it to the patients system in the same surge dose as though the period of time delay had not occurred. In other words, the patient ultimately gets the surge.
However, recent pharmacological investigations have shown that with many drugs the patient responds far better to sustained minute-incremental dosage, that is to say, very minute quantities administered at very short intervals continuously over sustained periods of time. This can be referred to, for want of a better term, as the trickle system. Such procedures have been recognized for quite some time with respect to liquid medications such as the trickle treatment with penicillin for syphilis. The use of conventional enteric coated tablets, however, for the reason heretofore set out will not achieve even an approxiation of sustained minute-incremental dosage.
*It is the primary object of the present invention, therefore, to provide a pharmaceutical preparation having a unique and novel composition and structure, which, as a result of a drug or medicament, can be administered in a persistent sustained incremental dosage. V i
It is also an object of the present invention to provide a pharmaceutical preparation which is capable of maintaining a desired level of medication within the patients system over prolonged periods of time.
It is a further object of the present invention to provide a pharmaceutical preparation which has a unique and novel compositiohzand structure, which is simple and precise in its actionnand which is economical to produce. I 'l It is also an object of the present invention to provide methods ofmaking pharmaceutical preparations of the type stated.
With the above and other objects in view, my invention resides in the novel features of form, construction, arrangement, and combination of parts presently described and pointed out in the claims.
Broadly speaking, the present invention resides in the discovery that a pharmaceutical preparation adapted for sustained minute-incremental dosage can be made by intimately mixing various enteric water insoluble excipients, such as shellac, with powdered drugs to form a somewhat pasty mass which is then spread on drying trays and dried to produce a rough granular material. This granular material is crushed and remixed with the excipient to form a pasty mass which is then spread on trays and dried again to form .a rough granular material. This procedure of crushing, mixing with excipient, and tray-drying is repeated a number of times and finally the end product is screened to produce agranular material having granules of substantially uniform size. It has been found that, in such granules, the excipient and the medicament are intimately mixed or. dispersed throughout the mass of each granule in the form of very minute particles. Visual examination of the granules under high-magnification shows that the surface thereof is not covered with a continuous film of the dried excipient or a continuous film of the medicament, but,
rather, is dotted with minute particles of the dried excipient and minute particles of the medicament in a sort of heterogeneous arrangement. Furthermore, this general physical structure exists throughout the granule. By both in vitro tests and blood'level studies, it has been established that these granules, when in the human stomach and intestinal tract are neither soluble or insoluble in the strictest sense of these terms, but, instead, the medicament leaches out steadily in minute increments or doses, that is to say, as a sustained trickle.
While this invention is not intended to be limited thereby, the following are examples of pharmaceutical preparations which can be made in accordance with the present invention:
Example I enough shellac (of the,type above) until a pasty mass results. This mass is again placed on cloth drying trays .and dried, thereby again forming a granular mass as before. The above procedure is repeated for a total of eleventimes, using a total of about 12 gallon of shellac (dry solids content 46%). The-first four mixing-drying steps are repeated over a time cycle which involves about 7 to 10 hour drying periods and all subsequent mixing-drying steps include about 20 to 22 hour drying periods. These time periods can be speeded up by placing the drying trays in a hot room. The hot room should be maintained at about 100 to 120 F. with a relative humidity not in excess of 30% and the material dried until the granules are hard and frangible, that is to say, will :form fine-grained particles upon crushing. .Final yield is approximately 5.6 lbs. of granules of heterogeneous and irregular shapes.
Upon assay, the granules are-precisely uniform in constituency. :In other words, any given weight of granules will be found 'to contain theisarne dosage of amphetamine. Of course, each-batch should be assayed and the actual amphetamine content by weight or percentage determined. It has been found that by following a standardized manufacturing procedure, successive batches of granules have closely similar assays well Within admissible limits of pharmaceutical accuracy. However,
this is not overly important-since the granules thus formed are measured into capsules or tableted by conventional procedure for administration to the patient and any variations in drug content, as-shown'by the assay of the specific batch, can be taken into account in making up the capsule or tablet.
Example 1 1 Adry mixture of .3 oz. d-arnphetamine sulfate, .12 oz. secobarbital and 3 lbs. dicalcium phosphate is taken up with Shellac as per'Example I employing approximately 1 gallon shellac in eleven successive mixing-dryingsteps.
Yield approximately 5 /2 lbs. of granules.
Example III A dry mixture of 7 oz. pentobarbituric acid, 7 oz. phenobarbital and 2 oz. -d-amphetamine sulfate, 3 lbs. calcium carbonate is taken up in shellac as per Example I employing nine successive mixing-drying steps.
Example IV A. dry mixture of 2 oz. scopolamine aminoxidehydrobromide, and 5 lbs. dicalcium phosphate were taken up in shellac as per Example Iemploying-eleven successive mixing-dryingsteps.
Example V A dry mixture of 2 lbs. mephobarbital, 2 /2 oz. homatropine methylbromide, 1 oz. atropine methyl nitrate, /2 oz. hyoscine hydrobromide, and 6 lbs. kaolin were taken up in shellac as per Example I employing eleven successive mixing-drying steps.
Example VI A dry mixture of 4 lbs. mannitol hexanitrate 7% (with 13 parts lactose) was taken up in shellac as per Example I employing eleven successive mixing-drying steps.
Example VII A dry mixture of 3 lbs. pyralimine maleate and 1 lb. vitamin C were taken up in 60 oz. (liquid) of shellac as per Example I employing fifteen successive mixing-drying steps to produce 5.5 lbs. of finished granules. 275 mgs. of such granules were filled into a No. 3 capsule, giving a dosage of mgs. ,pyralimine maleate and 50 mgs. of vitamin C.
The above described procedure has been employed in making granules with a wide variety of drugs or medicinals, such as, for instance, scopolamine methylbromide, pentaerythritol tetranitrate, sodium nitrite, hexamethonium chloride, veratrum viride, reserpine, stilbesterol, methyl testosterone, phenobarbitol,pyralimine, digitoxin, caffeine, andantibiotics, such as penicillin,-and the like. In each instance, the quantity of the drug is calculated by usual arithmetic methods well known in pharmaceutical manufacturing. It should also be noted that, instead of dicalcium phosphate, other suitable inert carriers, such as calcium carbonate, tri-calcium phosphate, magnesium oxide, magnesium carbonate, kaolin, starch, or lactose, may be used. Where the drug or medicament has sufficient bulk, it-is even possible to eliminate the use of an inert carrier, as shown by Example VII.
It has also been found that other liquid excipients, such as a mixture of castor oil, stearic acid, and confectioners glaze (i. e. shellac), cellulose acetate phthalate in acetone, salol in alcohol, various balsams, such as tolu in alcohol, ethyl cellulose in methyl-ethylketone, or zein in isopropanol, can be employed in practicingthe herein described invention. Similarly, by'increasing-the number of. mixing-drying steps, it is possible to-slow down the rate of entry of the drug into the patients system and, conversely, by-lowering the number of-successive mixing-drying steps, it is possible to speed up the rate of entry of the drug into the patients system. However, it has been found that a minimum of such steps is two and a practical maximum is'fifteen, sinceadditional mixing-drying steps resulting in such a slow rate of drug absorption by the patient has beenfound to be impractical forpresently known medical purposes. Also, if desiredforthe sake of appearance, the granules can be placed in 'a coating pan and sugar coated with aplain or suitablycolored sugar glaze.
It is also possible tOlIlCOl'POI'flle liquid medicaments either by taking them'up in an inert carrier and ,then
granulating with shellac orother excipients as above described, or dissolving them in the liquid excipient and addingthis solution to an inert carrier to create the initial granules-and then-carrying out the repeated regranulationsusing such excipicnt solution until all-the drug bearing'excipient has been incorporated. Usually, this will take five or six mixing-drying steps. Thereafter, six to nine further successive mixing-drying steps are -em ployed using the-plain (i. e.-non-drng bearing) excipient.
It should be understood that changes and modifications intheform, construction, arrangement, and combination of the several parts of the pharmaceutical preparations maybe made and substituted-for those herein shown and described without departing from the nature-and principle of my invention.
Having thus described my invention, what I claim-and desire to secure by Letters Patent is:
if, u
L'The process for making sustained period minuteincremental dosage pharmaceutical preparations which comprises intimately mixing a powdered drug and shellac to produce a pasty mass, drying the mass slowlywithout agitation in such a manner as to produce a rough granular material, breaking up the rough granular material by light crushing, whereby to reduce it to granular particles, said mixing, drying and crushing operations constituting one cycle, and remixing the granular particles with an addiitonal quantity of the excipient to produce a pasty mass, redrying such pasty mass slowly and without agitation in such a manner as to produce a granular material, again breaking up the rough granular material by light crushing, whereby to reduce it again to granular particles, said second mixing, drying and crushing operations constituting a second cycle, said process consisting of not less than 3 nor more than mixing, crushing and drying cycles repeated in successive order, whereby to produce a pharmaceutical material consisting of granules having slow but continuous and attenuated solubility in the gastro-intestinal tract.
2. The process for making sustained period minuteincremental dosage pharmaceutical preparations which comprise intimately mixing a powdered drug and an enteric water insoluble excipient to produce a pasty mass, drying the mass slowly without agitation in such a manner as to produce a rough granular material, breaking up the rough granular material by light crushing, whereby to reduce it to granular particles, said mixing, drying and crushing operations constituting one cycle, and remixing the granular particles with an additional quantity of the excipient to produce a pasty mass, redrying such pasty mass slowly and without agitation in such a manner as to produce a granular material, again breaking up the rough granular material by light crushing, whereby to reduce it again to granular particles, said second mixing, drying and crushing operations constituting a second cycle, said process consisting of not less than 3 nor more than 15 mixing, crushing and drying cycles repeated in successive order, whereby to produce a pharmaceutical material consisting of granules having slow but continuous and attenuated solubility in the gastro-intestinal tract.
3. The process for making sustained period minuteincremental dosage pharmaceutical preparations which comprises intimately mixing a powdered drug and a water insoluble excipient consisting of a mixture of shellac and stearic acid, whereby to produce a pasty mass, drying the mass slowly without agitation in such a manner as to produce a rough granular material, breaking up the rough granular material by light crushing, whereby to reduce it to granular particles, said mixing, drying and crushing operations constituting one cycle, and remixing the granular particles with an additional quantity of the excipient to produce a pasty mass, redrying such pasty mass slowly and without agitation in such a manner as to produce a granular material, again breaking up the rough granular material by light crushing, whereby to reduce it again to granular particles, said second mixing,
drying and crushing operations constituting a second cycle, said process consisting of not less than three nor more than fifteen mixing, crushing and drying cycles repeated in successive order, whereby to produce a pharmaceutical material consisting of granules having slow but 7 continuous and attenuated Solubility in the gastro-intestinal tract.
pasty mass, redrying such pasty mass slowly and without agitation in such a manner as to produce a granular material, again breaking up the rough granular material by light crushing, whereby to reduce it again to granular particles, said second mixing, drying and crushing opera tions constituting a second cycle, said process consisting of not less than three nor more than fifteen mixing, crushing and drying cycles repeated in successive order, whereby to produce a pharmaceutical material consisting of granules having slow but continuous and attenuated solubility in the gastro-intestinal tract.
5. The process for making sustained period minuteincremental dosage pharmaceutical preparations which comprises intimately mixing a powdered drug and an enteric water insoluble excipient to produce a pasty mass, spreading the mass in a thin layer upon trays and drying the mass slowly without agitation in such a manner as to produce a rough granular material, breaking up the rough granular material by light crushing, whereby toreduce to granular particles, said mixing, drying and crushing operations constituting one cycle, and remixing the granular particles with an additional quantity of the excipient to produce a pasty mass, redrying such pasty mass slowly and without agitation in such a manner as to produce a granular material, again breaking up the rough granular material by light crushing, whereby to reduce it again to granular particles, said second mixing, drying and crushing operations constituting a second cycle, said process consisting of not less than three nor more than fifteen mixing, crushing and drying cycles repeated insuccessive order, whereby to produce a pharmaceutical material consisting of granules having slow but continuous and attenuated solubility in the gastro-intestinal tract.
6. The process for making sustained period minuteincremental dosage pharmaceutical preparations which comprises intimately mixing a powdered drug and an enteric water insoluble excipient to produce a pasty mass, spreading the mass in a thin layer upon air pervious trays and drying the mass slowly without agitation in such a manner as to produce a rough granular material, breaking up the rough granular material by light crushing, whereby to reduce it to granular particles, said mixing, drying and crushing operations constituting one cycle, and remixing the granular particles with an additional quantity of the excipient to produce a pasty mass, redrying such pasty mass slowly and without agitation in such a manner as to produce a granular material, again breaking up the rough granular material by light crushing, whereby to reduce it again to granular particles, said second mixing, drying and crushing operations constituting a second cycle, said process consisting of not less than three nor more than fifteen mixing, crushing and drying cycles repeated in successive order, whereby to produce a pharmaceutical material consisting of granules having slow but continuous and attenuated solubility in the gastro-intestinal tract.
7. The process for making sustained period minutemcremental dosage pharmaceutical preparations which comprises intimately mixing a powdered drug and an enteric water insoluble excipient to produce a pasty mass, spreading the mass in a thin layer upon cloth bottomed trays and drying the mass slowly without agitation in such a manner as to produce :a rough granular material, breaking up the rough granular material by light crushing, whereby to reduce it to granular particles, said mixing, drying and crushing operations constitutingone cycle, and remixing the granular particles with an additional quantity of the excipient to produce a pasty mass, redrying such pasty mass slowly and without agitation in such a manner as to produce a granular material, again breaking up the rough granular material by light crushing, whereby to reduce it again to granular particles, said second mixing, drying and crushing operations constituting a second cycle, said process consisting of not less than three nor more than fifteen mixing, crushing and drying cycles repeated in successive order, whereby to produce a pharmaceutical vmaterial consisting of granules having slow but --contin,uous and ,-attenuated solubility in the gastroint tinal. tr ct.
i8.-,'1"he process for making sustained period minuteincremental dosage pharmaceutical preparations which eomprises intimately mixing a powdered drug and an enteric water insoluble excipient to produce a pasty mass, drying the mass slowly Without, agitation in a hot dry atmosphere in .such a manner as to produce a rough granular material, breaking up the rough granular material by light crushing, ,whereby'to reduce it to granular particles, said mixing, drying and crushing operations constituting one cycle, and remixing the granular particles ,Withan additional quantity of the excipient to produce a pasty mass, redrying such pasty mass slowly and without agitation in such a manner as to produce a granular-,material, again breaking up the rough granular material by light crushing, whereby to reduce it again to granular particles,.=said second mixing, drying and crushing operations constituting a second cycle, said process consisting of not less than three nor more than fifteen mixing, Crushing and drying cycles repeated in successive order, whereby to produce a pharmaceutical material consisting of granules having slow but continuous and attenuated solubility in the gastro-intestinal tract.
9. Theprocess for making sustained period minuteincremental dosage pharmaceutical preparations which comprises intimately mixing a powdered drug and an enteric water insoluble excipient to produce apasty mass,
drying-themass slowly without agitation in such a manner as to producea rough granular material, breaking up the rough granular material by light crushing, whereby t0 edu it t nu particles, s d K-. ng ;d .yins a q ush er ti n t utinsqn cyqle and maritime t nul Pa cle wi -adsi t na ua it fzth excipientto produce a pasty mass, redrying suehpasty mass slowly and-without agitation in sueh a manner as to produce a granular material, again breaking up;the rough granular material by light crushing, ,wherebyto reduce it again to granularparticles, said secondrnixing, drying and crushing operations constituting a second cycle, said process consisting of not less tha nfi nor more than 15 mixing, crushing and drying cycles repeated in successive order, whereby to produce a pharmaceutical material consisting of granules having slow but continuous and attenuated solubility in the gastro-intestinal tract, and coating the particles with asugar'glaze.
10. A pharmaceutical preparation made in-accordance with the process of claim 1.
11. A pharmaceutical preparation made in accordance with the process of claim 2.
12. A pharmaceutical preparatiommade inaecordance with the process of claim 3.
References Cited in thefile of this patent UNETED STATES PATENTS 1,012,788 Zwingenberger Dec.'2 6, 1911 2,052,376 Zellers Aug. 25, 1936 2,191,678 Nitardyet a1 Feb. 27, 1940 2,736,682 Hermelin Feb. 28, 1956 OTHER REFERENCES Little et al.: Tablet Making (Liverpool, 1949), pp. 42 and 43.
Claims (1)
- 2. THE PROCESS FOR MAKING SUSTAINED PERIOD MINUTE INCREMENTAL DOSAGE PHARMACEUTICAL PREPARATIONS WHICH COMPRISE INTIMATELY MIXING A POWDERED DRUG AND AN ENTERIC WATER INSOLUBLE EXCIPIENT TO PRODUCE A PASTY MASS, DRYING THE MASS SLOWLY WITHOUT AGITATION IN SUCH A MANNER AS TO PRODUCE A ROUGH GRANULAR MATERIAL, BREAKING UP THE ROUGH GRANULAR MATERIAL BY LIGHT CRUSHING, WHEREBY TO REDUCE IT TO GRANULAR PARTICLES,SAID MIXING, DRYING AND CRUSHING OPERATIONS CONSTITUTING ONE CYCLE, AND REMIXING THE GRANULAR PARTICLES WITH AN ADDITIONAL QUANTITY OF THE EXCIPIENT TO PRODUCE A PASTY MASS, REDRYING SUCH PASTY MASS SLOWLY AND WITHOUT AGITATION IN SUCH A MANNER AS TO PRODUCE A GRANULAR MATERIAL, AGAIN BREAKING UP TO ROUGH GRANULAR MATERIAL BY LIGHT CRUSHING, WHEREBY TO REDUCE IT AGAIN TO GRANULAR PARTICLES, SAID SECOND MIXING, DRYING AND CRUSHING OPERATIONS CONSTITUTING A SECOND CYCLE, SAID PROCESS CONSISTING OF NOT LESS THAN 3 NOR MORE THAN 15 MIXING, CRUSHING AND DRYING CYCLES REPEATED IN SUCCESSIVE ORDER, WHEREBY TO PRODUCE A PHARMACEUTICAL MATERIAL CONSISTING OF GRANULES HAVING SLOW BUT CONTINUOUS AND ATTENUATED SOLUBILITY IN THE GASTRO-INTESTINAL TRACT.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US541027A US2809916A (en) | 1955-10-17 | 1955-10-17 | Sustained release pharmaceutical preparations |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US541027A US2809916A (en) | 1955-10-17 | 1955-10-17 | Sustained release pharmaceutical preparations |
Publications (1)
Publication Number | Publication Date |
---|---|
US2809916A true US2809916A (en) | 1957-10-15 |
Family
ID=24157898
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US541027A Expired - Lifetime US2809916A (en) | 1955-10-17 | 1955-10-17 | Sustained release pharmaceutical preparations |
Country Status (1)
Country | Link |
---|---|
US (1) | US2809916A (en) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3132067A (en) * | 1960-03-31 | 1964-05-05 | Rauscher Herbert | Metal phosphide compositions and a process for their production |
US3485914A (en) * | 1966-07-05 | 1969-12-23 | Chem & Pharm Patent Hold Ltd | Process for the production of a pharmaceutical antibiotic preparation having delayed therapeutic action and the composition prepared according to such process |
US3499959A (en) * | 1966-07-05 | 1970-03-10 | Chem & Pharm Patent Hold Ltd | Therapeutic tetracycline preparation having delayed therapeutic action and processes for the production of said preparation |
US4421742A (en) * | 1977-02-08 | 1983-12-20 | Dr. Werner Freyberg Chemische Fabrik Delitia Nachf. | Phosphine producing pesticide and method of manufacture therefor |
EP0235986A1 (en) * | 1986-02-13 | 1987-09-09 | Ethical Pharmaceuticals Limited | Slow release formulation |
US4837032A (en) * | 1986-02-04 | 1989-06-06 | Farval Ag | Theophylline sustained release tablet |
US5077051A (en) * | 1990-04-10 | 1991-12-31 | Warner-Lambert Company | Sustained release of active agents from bioadhesive microcapsules |
WO1995002394A1 (en) * | 1993-07-13 | 1995-01-26 | Church & Dwight Company, Inc. | Co-micronized bicarbonate salt compositions |
US5879714A (en) * | 1996-04-24 | 1999-03-09 | Bernard Charles Sherman | Controlled-release pharmaceutical compositions |
US20060147526A1 (en) * | 2002-11-29 | 2006-07-06 | Cipla Limted | Pharmaceutical formulations comprising ß-2 adrenoreceptor agonists and xanthines |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1012788A (en) * | 1909-04-22 | 1911-12-26 | Otto K Zwingenberger | Medicinal composition containing oil. |
US2052376A (en) * | 1933-05-18 | 1936-08-25 | Edgar G Zellers | Insoluble pill or tablet for internal medicinal uses |
US2191678A (en) * | 1938-04-02 | 1940-02-27 | Squibb & Sons Inc | Process of preparing tablets |
US2736682A (en) * | 1954-10-11 | 1956-02-28 | Victor M Hermelin | Method of making a prolonged action medicinal tablet |
-
1955
- 1955-10-17 US US541027A patent/US2809916A/en not_active Expired - Lifetime
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1012788A (en) * | 1909-04-22 | 1911-12-26 | Otto K Zwingenberger | Medicinal composition containing oil. |
US2052376A (en) * | 1933-05-18 | 1936-08-25 | Edgar G Zellers | Insoluble pill or tablet for internal medicinal uses |
US2191678A (en) * | 1938-04-02 | 1940-02-27 | Squibb & Sons Inc | Process of preparing tablets |
US2736682A (en) * | 1954-10-11 | 1956-02-28 | Victor M Hermelin | Method of making a prolonged action medicinal tablet |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3132067A (en) * | 1960-03-31 | 1964-05-05 | Rauscher Herbert | Metal phosphide compositions and a process for their production |
US3485914A (en) * | 1966-07-05 | 1969-12-23 | Chem & Pharm Patent Hold Ltd | Process for the production of a pharmaceutical antibiotic preparation having delayed therapeutic action and the composition prepared according to such process |
US3499959A (en) * | 1966-07-05 | 1970-03-10 | Chem & Pharm Patent Hold Ltd | Therapeutic tetracycline preparation having delayed therapeutic action and processes for the production of said preparation |
US4421742A (en) * | 1977-02-08 | 1983-12-20 | Dr. Werner Freyberg Chemische Fabrik Delitia Nachf. | Phosphine producing pesticide and method of manufacture therefor |
US4600584A (en) * | 1977-02-08 | 1986-07-15 | Dr. Werner Freyberg Chemische Fabrik Delitia Nachf | Phosphine producing hydrolyzable metal phosphide and use thereof |
US4837032A (en) * | 1986-02-04 | 1989-06-06 | Farval Ag | Theophylline sustained release tablet |
JPS62215519A (en) * | 1986-02-13 | 1987-09-22 | エチカル・フアーマシユーテイカルズ・リミテツド | sustained release composition |
EP0235986A1 (en) * | 1986-02-13 | 1987-09-09 | Ethical Pharmaceuticals Limited | Slow release formulation |
US4880830A (en) * | 1986-02-13 | 1989-11-14 | Ethical Pharmaceuticals Limited | Slow release formulation |
JPH0655669B2 (en) * | 1986-02-13 | 1994-07-27 | エチカル・フアーマシユーテイカルズ・リミテツド | Sustained release composition |
US5077051A (en) * | 1990-04-10 | 1991-12-31 | Warner-Lambert Company | Sustained release of active agents from bioadhesive microcapsules |
WO1995002394A1 (en) * | 1993-07-13 | 1995-01-26 | Church & Dwight Company, Inc. | Co-micronized bicarbonate salt compositions |
US5879714A (en) * | 1996-04-24 | 1999-03-09 | Bernard Charles Sherman | Controlled-release pharmaceutical compositions |
US20060147526A1 (en) * | 2002-11-29 | 2006-07-06 | Cipla Limted | Pharmaceutical formulations comprising ß-2 adrenoreceptor agonists and xanthines |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US2809918A (en) | Sustained release pharmaceutical preparations | |
CA1054056A (en) | Solid therapeutic preparation remaining in stomach | |
US3081233A (en) | Enteric-coated pilules | |
EP0129382B1 (en) | Long-acting formulation of cefaclor and its preparation | |
RU2686840C1 (en) | Solid dosage forms of pallbocyclob | |
AU593038B2 (en) | New drug preparation with controlled release of the active compound, a method for the manufacture thereof and the use of the new preparation | |
US2793979A (en) | Method of making a sustained release pharmaceutical tablet and product of the method | |
US4684516A (en) | Sustained release tablets and method of making same | |
KR100671275B1 (en) | Finely divided eplerenone composition | |
US3402240A (en) | Medicinal tablet and process of making same | |
US2928770A (en) | Sustained action pill | |
EP1067936B1 (en) | Formulation of fast-dissolving efavirenz capsules or tablets using super-disintegrants | |
JP3010562B2 (en) | Sustained-release preparation unit | |
CA1323576C (en) | Long acting diclofenac sodium preparation | |
US2809917A (en) | Sustained release pharmaceutical tablets | |
JPH01226821A (en) | Drug form of tetracycline | |
JPH0759500B2 (en) | Diffusion coated composite unit dose | |
US2809916A (en) | Sustained release pharmaceutical preparations | |
NZ204856A (en) | Analgesic capsules containing aspirin and p-acetylaminophenol | |
US3078216A (en) | Prolonged release oral pharmaceutical preparations | |
US3328256A (en) | Spherical beads and their production | |
US3524910A (en) | Sustained relief analgesic compositions | |
RU2451504C2 (en) | Method for production of multiparticles using roller compactor | |
CA1216523A (en) | Sustained-release product containing suloctidil | |
WO2008083561A1 (en) | Oral pharmaceutical composition of glycyrrhizin or its salts and the preparation method thereof |